Table 2.
Clinical features and Response in 22 Elderly/Frail patients with DLBCL, treated upfront with R-DEVEC.
| Factors | B-cell Lymphoma (n = 22) n (%) |
|---|---|
| Median Age (range) | 84.5 (77–93) |
| Male | 14 (64) |
| Stage III-IV | 19 (86) |
| Ecog PS 1 | 5 (22) |
| PS 2 | 13 (59) |
| PS 3 | 4 (18) |
| Hemoglobin <12 g/dL | 11 (50) |
| Albumin <3.5 g/dL | 11 (50) |
| Bulky ≥7.5cm [21] | 9 (41) |
| IPI 1–2 | 5 (22) |
| IPI 3 | 5 (22) |
| IPI 4–5 | 12 (54.5) |
| a CGA | Unfit = 1(4) |
| Frail = 15 (68) | |
| Super-Frail = 6 (27) | |
| b EPI | Int = 5 (22) |
| High = 17 (78) | |
| Histologic subtypes | DLBCL NOS = 2(9) |
| Non-GC-type = 9 (41) | |
| GCB-type = 7 (32) | |
| Transformed-NHL = 3 (14) | |
| CHL/DLBCL = 1 (4) | |
| Interim Response | ORR = 17 (77) |
| PR = 10 (45) | |
| CR/CRu = 7 (32) | |
| NR = 3 (14) | |
| NE = 2 (9) | |
| Final Response | ORR = 14 (64) |
| PR = 0 | |
| CR = 14 (64) | |
| NR = 4 (18) | |
| NE = 4 (18) |
IPI 1–2; 3 and 4–5 international prognostic index score of 1–2; 3 and 4–5. a CGA: comprehensive geriatric assessment as defined by Merli and co-workers. b EPI: Elderly-IPI, from the Elderly Project of the Fondazione Italiana Linfomi by Merli and co-workers. DLBCL-NOS: diffuse large B-cell lymphoma without other specifications, Non-GC type: non germinal center type; GC-type: germinal center type on the basis of the Hans ‘algorithm [19]. CHL/DLBCL= histology with feature of both Hodgkin and non-Hodgkin lymphoma, ORR = Overall response, PR = partial response; CRu = Complete remission undetermined; NR = non-respondent; NE = not evaluable.